APX-343A / AptaBio - LARVOL DELTA

AptaBio Announces Results of Three Studies at AACR, Including CAF Targeting Therapy and Blood Cancer Treatment [Google translation] (BioTimes) - "At this AACR, AptaBio plans to present the research results of its anticancer drug ‘APX-343A’ with a CAF inhibition mechanism, as well as the first study to elucidate the mechanism of action of NOX2, which plays a critical role in regulating CAF and M2 macrophages in the tumor microenvironment (TME). In addition, it plans to disclose the scientific evidence supporting the claim that ‘Apta-16’, an innovative treatment applied with the Aptamer-drug conjugate (Apta-DC) platform technology, can provide a new treatment option for patients with relapsed and refractory acute myeloid leukemia."

Preclinical • Acute Myelogenous Leukemia

AptaBio, Immunotherapy Anticancer Drug ’APX-343A’ Acquires Patents in Japan and Mexico Simultaneously [Google translation] (BioTimes) - "AptaBio...announced on the 10th that it has simultaneously acquired material patents for its immunotherapy drug (APX-343A) in Japan and Mexico. This is the first patent acquisition in Australia, Russia, Chile, and the United States."

Patent • Oncology